CA-074 Me: Selective Cathepsin B Inhibitor for Lysosomal Pathway Research

Executive Summary: CA-074 Me is a methyl ester derivative of CA-074, developed for potent, selective, and membrane-permeable inhibition of cathepsin B (IC₅₀ = 36.3 nM) (APExBIO). It achieves 95% inhibition in cultured human gingival fibroblasts and complete inhibition in reducing conditions such as with DTT (Liu et al., 2024). CA-074 Me is widely used to investigate the role of cathepsin B in apoptosis, necroptosis, and lysosomal membrane permeabilization, especially in TNF-α-induced liver injury models. CA-074 Me is insoluble in water but highly soluble in DMSO (≥19.88 mg/mL) and ethanol (≥51.5 mg/mL with ultrasonic treatment). Chemical inhibition of cathepsin B using CA-074 Me has been shown to protect cells from necroptosis by blocking lysosomal enzyme release (Liu et al., 2024).

Biological Rationale

Necroptosis is a genetically programmed form of immunogenic cell death that is distinct from apoptosis. It is characterized by organelle swelling, plasma membrane rupture, and DAMP release. Necroptosis is triggered by factors such as tumor necrosis factor (TNF), particularly in the presence of Smac-mimetic and pan-caspase inhibitor Z-VAD-FMK (Liu et al., 2024). A core feature of necroptosis is the activation and polymerization of mixed lineage kinase-like protein (MLKL), which translocates to lysosomal membranes and induces lysosomal membrane permeabilization (LMP). LMP results in the release of lysosomal proteases, with cathepsin B (CTSB) being a key mediator of subsequent cell death events. Chemical inhibition of CTSB attenuates necroptosis and its downstream pathological sequelae. Therefore, selective inhibition of cathepsin B enables researchers to dissect the mechanistic contributions of lysosomal protease activity in cell death, inflammation, and organ injury.

Mechanism of Action of CA-074 Me

CA-074 Me is a methyl ester derivative of CA-074, conferring enhanced membrane permeability. Upon cell entry, the methyl ester is hydrolyzed, yielding the active CA-074 acid form that selectively targets cathepsin B. CA-074 Me binds to the active site cysteine of cathepsin B, inhibiting its proteolytic activity with an IC₅₀ of 36.3 nM (APExBIO). In reducing conditions (e.g., with 1 mM DTT), CA-074 Me achieves full inhibition of cathepsin B and can also inhibit cathepsin L (>90% after pre-incubation). Selectivity is highest for cathepsin B under physiological conditions, but partial cross-reactivity with cathepsin L is observed when strong reducing agents are present. This mechanism allows for precise control of lysosomal protease activity in cell-based and animal models, supporting its use in apoptosis, necroptosis, and inflammation research.

Evidence & Benchmarks

• CA-074 Me inhibits cathepsin B with an IC₅₀ of 36.3 nM in biochemical assays (APExBIO).
• In cultured human gingival fibroblasts, CA-074 Me achieves 95% inhibition of cathepsin B activity (Liu et al., 2024).
• In the presence of DTT or GSH (reducing conditions), complete inhibition of cathepsin B and >90% inhibition of cathepsin L are observed (APExBIO).
• Chemical inhibition or genetic knockdown of cathepsin B protects cells from necroptosis following MLKL polymerization-induced LMP (Liu et al., 2024).
• In TNF-α-induced liver injury mouse models, CA-074 Me attenuates hepatic damage and inflammatory responses (Liu et al., 2024).
• CA-074 Me displays good solubility in DMSO (≥19.88 mg/mL) and ethanol (≥51.5 mg/mL with ultrasonication), but is insoluble in water (APExBIO).

This article extends the mechanistic insights of CA-074 Me: Potent and Selective Cathepsin B Inhibitor for... by providing updated peer-reviewed evidence on necroptosis and MLKL-driven lysosomal signaling. For deeper mechanistic exploration of MLKL, lysosomal permeabilization, and necroptosis, see CA-074 Me: Unlocking Lysosomal Protease Inhibition in Nec..., which this article updates with new evidence on cell protection via cathepsin B inhibition.

Applications, Limits & Misconceptions

CA-074 Me is widely implemented in cell-based and animal models to study:

• Apoptosis and necroptosis assays involving lysosomal membrane permeabilization.
• Dissection of cathepsin B’s role in inflammation and organ injury, particularly in liver disease models.
• Pathway analysis of cathepsin signaling and lysosomal protease function.
• Screening for modulators of lysosomal stability and cell death pathways.

Common Pitfalls or Misconceptions

• CA-074 Me is not selective for cathepsin B under strongly reducing conditions; cathepsin L inhibition (>90%) can occur with DTT or GSH.
• It is insoluble in aqueous buffers; improper dissolution may affect assay reproducibility.
• Long-term storage in solution is not recommended; activity loss may occur if stored above -20°C or in solution for extended periods.
• CA-074 Me is not suitable as a pan-cathepsin inhibitor; it does not effectively inhibit cathepsins D, S, or other non-cysteine proteases.
• In vivo efficacy and pharmacokinetics should be carefully validated for each animal model; published liver injury data may not generalize to all tissues or disease contexts.

Workflow Integration & Parameters

For optimal use, CA-074 Me should be dissolved in DMSO (≥19.88 mg/mL) or ethanol (≥51.5 mg/mL, with ultrasonication). Stock solutions are best stored below -20°C and freshly diluted prior to assay (APExBIO). Typical working concentrations range from 1–50 μM, depending on cell type and protocol (CA-074 Me: Selective Cathepsin B Inhibitor for Lysosomal ...). For apoptosis, necroptosis, or inflammation models, pre-incubation (30–60 min) is recommended for maximal intracellular inhibition. Controls should include vehicle (DMSO/ethanol) and, where possible, genetic knockdown or alternative inhibitors to confirm specificity. Lysosomal integrity and cathepsin activity should be monitored using established biochemical or imaging assays (Liu et al., 2024).

Conclusion & Outlook

CA-074 Me (SKU: A8239), supplied by APExBIO, is a robust tool for probing cathepsin B function in apoptosis, necroptosis, and lysosomal membrane permeabilization. Its selectivity, cell permeability, and validated performance in peer-reviewed models make it a gold-standard reagent for cell death and inflammation research. CA-074 Me enables precise interrogation of lysosomal protease pathways and supports high-confidence data generation in both cell-based and animal studies. Future research may further clarify its role in translational models of organ injury and immune signaling.